2487.HK
Price:
$6.1
Market Cap:
$1.77B
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Industry
Biotechnology
IPO Date
2023-06-12
Stock Exchange
HKSE
Ticker
2487.HK
According to Cutia Therapeutics’s latest financial reports and current stock price. The company's current PE Ratio is -3.70. This represents a change of 57.89% compared to the average of -2.34 of the last 4 quarters.
The mean historical PE Ratio of Cutia Therapeutics over the last ten years is -3.28. The current -3.70 PE Ratio has changed 11.18% with respect to the historical average. Over the past ten years (40 quarters), 2487.HK's PE Ratio was at its highest in in the June 2023 quarter at -0.36. The PE Ratio was at its lowest in in the June 2025 quarter at -3.04.
Average
-3.28
Median
-3.63
Minimum
-4.50
Maximum
-1.35
Discovering the peaks and valleys of Cutia Therapeutics PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 232.56%
Maximum Annual PE Ratio = -1.35
Minimum Annual Increase = -51.56%
Minimum Annual PE Ratio = -4.50
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -4.50 | 232.56% |
| 2023 | -1.35 | -51.56% |
| 2022 | -2.79 | -37.66% |
The current PE Ratio of Cutia Therapeutics (2487.HK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.88
5-year avg
-3.28
10-year avg
-3.28
Cutia Therapeutics’s PE Ratio is greater than HighTide Therapeutics Inc (-4.23), less than Frontage Holdings Corporation (72.18), greater than SinoMab BioScience Limited (-10.42), less than Clover Biopharmaceuticals, Ltd. (-3.55), greater than Mabpharm Limited (-80.50), greater than Zhaoke Ophthalmology Limited (-5.61), greater than Shanghai Bio-heart Biological Technology Co., Ltd. (-15.59), less than JW (Cayman) Therapeutics Co. Ltd (-1.88), less than Jiangsu Recbio Technology Co., Ltd. (-3.65), greater than Immunotech Biopharm Ltd (-6.57),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.23 | $1.71B | |
| 72.18 | $2.09B | |
| -10.42 | $1.82B | |
| -3.55 | $3.66B | |
| -80.50 | $2.43B | |
| -5.61 | $1.72B | |
| -15.59 | $1.48B | |
| -1.88 | $1.28B | |
| -3.65 | $2.63B | |
| -6.57 | $1.61B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cutia Therapeutics using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cutia Therapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cutia Therapeutics's PE Ratio?
How is the PE Ratio calculated for Cutia Therapeutics (2487.HK)?
What is the highest PE Ratio for Cutia Therapeutics (2487.HK)?
What is the 3-year average PE Ratio for Cutia Therapeutics (2487.HK)?
What is the 5-year average PE Ratio for Cutia Therapeutics (2487.HK)?
How does the current PE Ratio for Cutia Therapeutics (2487.HK) compare to its historical average?